What is the current Europe Pharmaceutical Contract Manufacturing Market size?

In 2024, the Europe Pharmaceutical Contract Manufacturing Market size is expected to reach USD 43.02 billion. Read More

Who are the key players in Europe Pharmaceutical Contract Manufacturing Market?

Fareva Holding SA, Recipharm AB, Boehringer Ingelheim Group, Aenova Group and Famar SA are the major companies operating in the Europe Pharmaceutical Contract Manufacturing Market. Read More

What years does this Europe Pharmaceutical Contract Manufacturing Market cover, and what was the market size in 2023?

In 2023, the Europe Pharmaceutical Contract Manufacturing Market size was estimated at USD 40.86 billion. The report covers the Europe Pharmaceutical Contract Manufacturing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Pharmaceutical Contract Manufacturing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Europe Pharmaceutical Contract Manufacturing Market

Europe Pharmaceutical Contract Manufacturing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Europe Pharmaceutical Contract Manufacturing Market Report is Segmented by Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, and Secondary Packaging) and Country (United Kingdom, Germany, France, Italy, and Rest of Europe). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Europe Pharmaceutical Contract Manufacturing Industry Overview

The European pharmaceutical contract manufacturing market is consolidated and consists of a few players. In terms of market share, top companies have control over the market. Major players include Fareva Holdings SA, Recipharm AB, Boehringer Ingelheim Group, Aenova Group, Famar SA, and Lonza Group.

May 2024: EUROAPI, a pharmaceutical company, signed a CMO agreement with a global animal health company. Under this partnership, EUROAPI supplies veterinary products to its clients. The contract's total value is estimated to be between EUR 130 million and EUR 150 million from 2025 to 2029.
November 2023: NorthEdge invested in Torbay Pharmaceuticals (Torbay), a contract manufacturer and license holder specializing in sterile injectables, from Torbay and Devon NHS Foundation Trust. This investment aims to support Torbay's next phase of international expansion. Torbay has experienced rapid growth, driven by increasing demand for commercial-scale sterile injectable fill/finish services. The company supplies healthcare organizations and pharmaceutical firms in the United Kingdom and internationally.